Aktienanalyse wird geladen …
A · NYSE · Diagnostics & Research · USA
172,84 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 6,95 Mrd. | 1,3 Mrd. | 4,57 $ | 285 Mio. | 0,7 Mio · 0,3 % | 6,7 Mio · 2,4 % | 52,4 % | 18,8 % | 4,04 $ | 0,45 $ | 0,99 $ |
| 2024 | 6,51 Mrd. | 1,29 Mrd. | 4,43 $ | 291 Mio. | 0,7 Mio · 0,3 % | 5,7 Mio · 2 % | 54,3 % | 19,8 % | 4,72 $ | 0,44 $ | 0,94 $ |
| 2023 | 6,83 Mrd. | 1,24 Mrd. | 4,19 $ | 296 Mio. | 0,6 Mio · 0,2 % | 4,6 Mio · 1,6 % | 50,7 % | 18,2 % | 4,98 $ | 0,38 $ | 0,90 $ |
| 2022 | 6,85 Mrd. | 1,25 Mrd. | 4,18 $ | 300 Mio. | 0,7 Mio · 0,2 % | 7,7 Mio · 2,6 % | 54,4 % | 18,3 % | 3,40 $ | 0,42 $ | 0,84 $ |
| 2021 | 6,32 Mrd. | 1,21 Mrd. | 3,94 $ | 307 Mio. | 0,6 Mio · 0,2 % | 5,6 Mio · 1,8 % | 53,9 % | 19,2 % | 4,22 $ | 0,36 $ | 0,78 $ |
| 2020 | 5,34 Mrd. | 719 Mio. | 2,30 $ | 312 Mio. | 0,5 Mio · 0,2 % | 6,5 Mio · 2,1 % | 53,1 % | 13,5 % | 2,57 $ | 0,27 $ | 0,72 $ |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|
| Q3 2026 | 1,88 Mrd. | 362 Mio. | 1,28 $ | 283 Mio. | 19,3 % | 1,55 $ |
| Q2 2026 | 1,84 Mrd. | 339 Mio. | 1,20 $ | 283 Mio. | 18,5 % | 0,71 $ |
| Q1 2026 | 1,8 Mrd. | 305 Mio. | 1,07 $ | 284 Mio. | 17 % | 0,62 $ |
| Q4 2025 | 1,86 Mrd. | 434 Mio. | 1,52 $ | 284 Mio. | 23,3 % | 1,59 $ |
| Q3 2025 | 1,74 Mrd. | 336 Mio. | 1,18 $ | 285 Mio. | 19,3 % | 0,91 $ |
| Q2 2025 | 1,67 Mrd. | 215 Mio. | 0,75 $ | 285 Mio. | 12,9 % | 0,38 $ |
| Q1 2025 | 1,68 Mrd. | 318 Mio. | 1,11 $ | 287 Mio. | 18,9 % | 1,16 $ |
| Q4 2024 | 1,7 Mrd. | 351 Mio. | 1,23 $ | — | 20,6 % | 1,36 $ |
If You Invested $1000 in Agilent Technologies a Decade Ago, This is How Much It'd Be Worth Now
Agilent Technologies Sees Growth From China, Replacement Cycles and Lab Automation
Research Tools & Consumables Stocks Q2 Highlights: Agilent (NYSE:A)
Capitalize on Label-Free Array Systems Disruption: Benchmark Agilent, Cytiva, Sartorius, Bio-Rad and PerkinElmer to Secure R&D ROI and Global Market Share
Capitalize on the Label-Free Detection Market Shift: Track How Danaher, Sartorius, Agilent, Bruker and Revvity Are Disrupting R&D ROI and Reshaping Global Revenue Through 2030
Agilent Launches TapeStationDx Systems for Clinical NGS Sample Quality Control
Goldman Sachs Adjusts PT on Agilent Technologies to $185 From $175, Maintains Buy Rating
Agilent (A) Wants Pathology Labs To Go Digital, 540 Slides At A Time
Agilent Technologies Inc. is a global life sciences, diagnostics, and applied markets company that provides instruments, software, consumables, and services for laboratory and analytical workflows. Its portfolio supports research, routine testing, and regulated environments across pharmaceuticals, clinical diagnostics, food safety, environmental analysis, and materials science. The company’s offerings include chromatography and mass spectrometry systems, spectroscopy tools, pathology and genomics solutions, laboratory informatics, and a broad range of consumables and support services. Agilent Technologies Inc. serves scientific, industrial, and healthcare customers that rely on precise measurement, sample analysis, and workflow efficiency. Through its lab-focused product and service mix, the company plays a central role in enabling data-driven decisions in research, quality control, and diagnostic testing across global markets.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest A und jede andere Aktie unbegrenzt.